Last reviewed · How we verify
SSGJ-707
SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway.
SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | SSGJ-707 |
|---|---|
| Sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SSGJ-707 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
- Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer (PHASE2)
- A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (PHASE1, PHASE2)
- A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer (PHASE2, PHASE3)
- SSGJ-707 in Advanced Non-Small Cell Lung Cancer (PHASE3)
- A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSGJ-707 CI brief — competitive landscape report
- SSGJ-707 updates RSS · CI watch RSS
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. portfolio CI